Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apixaban - Bristol-Myers Squibb/Pfizer

Drug Profile

Apixaban - Bristol-Myers Squibb/Pfizer

Alternative Names: BMS-562247; BMS-562247-01; Eliquis

Latest Information Update: 19 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Massachusetts General Hospital; Pfizer
  • Class 2 ring heterocyclic compounds; Amides; Anticoagulants; Antithrombotics; Cardiovascular therapies; Lactams; Phenyl ethers; Pyrazoles; Pyridones; Small molecules; Vascular disorder therapies
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Phase III Acute coronary syndromes
  • Phase II Heparin-induced thrombocytopenia and thrombosis syndrome

Most Recent Events

  • 17 Mar 2019 Safety data from the phase IV AUGUSTUS trial in Acute coronary syndromes released by Pfizer
  • 30 Nov 2018 Phase-II clinical trials in Heparin-induced thrombocytopenia and thrombosis syndrome in USA (PO) (NCT03594045)
  • 10 Nov 2018 Pfizer completes the phase IV AUGUSTUS trial in Acute coronary syndromes in Canada, USA, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, Colombia, Croatia, Czech Republic, Denmark, Germany, France, Hungary, India, Israel, Italy, South Korea, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, Spain, Sweden, Switzerland, Ukraine, United Kingdom and Virgin Islands (PO) (NCT02415400)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top